This company has been marked as potentially delisted and may not be actively trading. FS Development (FSDC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock FSDC vs. MOR, GMTX, CALT, ZYME, SBTX, MBX, AVTE, BIOA, NLTX, and CYBNShould you be buying FS Development stock or one of its competitors? The main competitors of FS Development include MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), BioAge Labs (BIOA), Neoleukin Therapeutics (NLTX), and Cybin (CYBN). FS Development vs. Its Competitors MorphoSys Gemini Therapeutics Calliditas Therapeutics AB (publ) Zymeworks Silverback Therapeutics MBX Biosciences Aerovate Therapeutics BioAge Labs Neoleukin Therapeutics Cybin MorphoSys (NASDAQ:MOR) and FS Development (NASDAQ:FSDC) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends. Do insiders and institutionals have more ownership in MOR or FSDC? 18.4% of MorphoSys shares are held by institutional investors. Comparatively, 89.8% of FS Development shares are held by institutional investors. 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has preferable valuation & earnings, MOR or FSDC? FS Development has lower revenue, but higher earnings than MorphoSys. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMorphoSys$238.28M11.99-$205.35M-$3.48-5.45FS DevelopmentN/AN/AN/AN/AN/A Is MOR or FSDC more profitable? FS Development has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. FS Development's return on equity of 0.00% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MorphoSys-226.79% -694.31% -22.55% FS Development N/A N/A N/A Does the media favor MOR or FSDC? In the previous week, MorphoSys' average media sentiment score of 0.00 equaled FS Development'saverage media sentiment score. Company Overall Sentiment MorphoSys Neutral FS Development Neutral SummaryFS Development beats MorphoSys on 4 of the 6 factors compared between the two stocks. Get FS Development News Delivered to You Automatically Sign up to receive the latest news and ratings for FSDC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FSDC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FSDC vs. The Competition Export to ExcelMetricFS DevelopmentPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$748.71M$934.71M$5.86B$10.14BDividend YieldN/A4.84%5.68%4.59%P/E RatioN/A1.1074.5225.93Price / SalesN/A26.70547.62126.81Price / CashN/A19.5637.5660.44Price / BookN/A6.6912.166.29Net IncomeN/A-$4.50M$3.28B$270.77M FS Development Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FSDCFS DevelopmentN/A$59.82-0.8%N/A+24.3%$748.71MN/A0.00N/AMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730GMTXGemini TherapeuticsN/A$60.34-2.5%N/A+24.3%$2.61BN/A-60.3430High Trading VolumeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180News CoverageZYMEZymeworks2.378 of 5 stars$15.79+3.9%$21.43+35.7%+29.2%$1.19B$122.87M-10.51460Positive NewsSBTXSilverback TherapeuticsN/A$10.32-3.6%N/A-19.6%$372.12MN/A-4.2683News CoverageHigh Trading VolumeMBXMBX Biosciences2.8039 of 5 stars$10.10-1.6%$37.63+272.5%N/A$339.47MN/A-2.2336Positive NewsAVTEAerovate TherapeuticsN/A$7.62+1.9%N/A-88.2%$220.87MN/A-2.5520Positive NewsHigh Trading VolumeBIOABioAge Labs0.1972 of 5 stars$4.95+2.7%N/AN/A$177.46MN/A0.00N/ANLTXNeoleukin TherapeuticsN/A$18.60-3.4%N/A-50.2%$174.80MN/A-5.9890CYBNCybin2.668 of 5 stars$6.25-0.6%$85.00+1,261.1%N/A$147.67MN/A-1.4350 Related Companies and Tools Related Companies MorphoSys Competitors Gemini Therapeutics Competitors Calliditas Therapeutics AB (publ) Competitors Zymeworks Competitors Silverback Therapeutics Competitors MBX Biosciences Competitors Aerovate Therapeutics Competitors BioAge Labs Competitors Neoleukin Therapeutics Competitors Cybin Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FSDC) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FS Development Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share FS Development With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FSDC Stock Alerts